新辅助紫杉醇和吉西他滨用于无法接受FOLFIRINOX方案治疗的可切除边缘或局部晚期不可切除胰腺腺癌患者。
Neoadjuvant -paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX.
作者信息
Peterson Shawn L, Husnain Muhammad, Pollack Terri, Pimentel Agustin, Loaiza-Bonilla Arturo, Westendorf-Overley Colleen, Ratermann Kelley, Anthony Lowell, Desimone Philip, Goel Gaurav, Kudrimoti Mahesh, Dineen Sean, Tzeng Ching-Wei D, Hosein Peter J
机构信息
University of Louisville, James Graham Brown Cancer Center, Louisville, KY, U.S.A.
University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, U.S.A.
出版信息
Anticancer Res. 2018 Jul;38(7):4035-4039. doi: 10.21873/anticanres.12692.
BACKGROUND/AIM: Combination nab-paclitaxel/gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX.
PATIENTS AND METHODS
This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery.
RESULTS
Between 10/2013-2/2018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had R0 resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease.
CONCLUSION
In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.
背景/目的：在转移性胰腺癌（PC）患者中，纳米白蛋白结合型紫杉醇/吉西他滨联合方案（AG）优于吉西他滨。关于AG用于可切除边缘（BR）或局部晚期胰腺癌（LAPC）的数据有限。在此，我们报告了在不符合FOLFIRINOX治疗条件的患者中，使用AG进行新辅助治疗BR/LAPC的经验。
患者与方法
本回顾性系列研究纳入了接受AG作为新辅助治疗3 - 4个月，随后进行放疗，然后重新评估手术的BR/LAPC患者。
结果
在2013年10月至2018年2月期间，32例患者（22例BR，10例LAPC）接受了这种治疗方法。中位年龄为70岁。9例患者经影像学检查转为可切除；6例实现R0切除（19%），5例（16%）获得部分缓解，24例（75%）病情稳定。
结论
在这个小系列研究中，R0切除率和缓解率分别为19%和16%。这些数据表明，新辅助AG可能是不符合FOLFIRINOX治疗条件患者的另一种选择。
Zotero 插件